Analyst Price Targets — ALVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:24 pm | Glen Santangelo | Barclays | $5.00 | $5.45 | TheFly | Alvotech initiated with an Underweight at Barclays |
| December 3, 2025 11:32 am | — | Morgan Stanley | $10.00 | $4.60 | TheFly | Alvotech price target lowered to $10 from $14 at Morgan Stanley |
| November 18, 2025 2:33 pm | — | UBS | $10.00 | $5.11 | TheFly | Alvotech price target lowered to $10 from $13 at UBS |
| November 4, 2025 1:17 pm | — | Northland Securities | $10.00 | $4.93 | TheFly | Alvotech price target lowered to $10 from $28 at Northland |
| November 4, 2025 9:49 am | Niall Alexander | Deutsche Bank | $8.00 | $5.03 | StreetInsider | Deutsche Bank Downgrades Alvotech SA (ALVO) to Hold |
| October 14, 2025 8:38 am | — | Morgan Stanley | $14.00 | $7.97 | TheFly | Alvotech upgraded to Overweight from Equal Weight at Morgan Stanley |
| May 24, 2024 5:26 am | Balaji Prasad | Barclays | $22.00 | $13.58 | TheFly | Alvotech price target raised to $22 from $20 at Barclays |
| May 21, 2024 2:22 pm | Balaji Prasad | Barclays | $20.00 | $13.76 | StreetInsider | Barclays Reiterates Overweight Rating on Alvotech SA (ALVO) |
| January 29, 2024 3:32 am | Balaji Prasad | Barclays | $17.00 | $15.25 | StreetInsider | Barclays Upgrades Alvotech SA (ALVO) to Overweight |
| July 1, 2022 5:05 am | Emmanuel Papadakis | Deutsche Bank | $10.00 | $8.21 | TheFly | Alvotech initiated with a Hold at Deutsche Bank |
Latest News for ALVO
Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers.
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC's website, www.sec.gov, as well as in the investor relations section of Alvotech's website at…
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech's website at: https://investors.alvotech.com/financials and is attached to this announcement in PDF and iXBRL formats.
Shares of Alvotech (NASDAQ: ALVO - Get Free Report) have been assigned an average rating of "Hold" from the six analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the
Alvotech (NASDAQ: ALVO) executives used the company's fourth-quarter and full-year 2025 earnings call to outline progress on commercial launches, manufacturing and quality initiatives tied to recent U.S. regulatory setbacks, and a 2026 outlook that assumes continued growth outside the United States. 2025 highlights and leadership transition Founder and Executive Chairman Róbert Wessman said 2025 strengthened…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ALVO.
Senate Trading
No Senate trades found for ALVO.
U.S. House Trading
No House trades found for ALVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.